



Molecular Targeted Therapy in Cancer

Guest Editor:

Prof. Dr. Sayed K. Goda

College of Science and
Engineering, University of Derby,
Derby, UK

Deadline for manuscript
submissions:

15 December 2024

Message from the Guest Editor

Molecular targeted cancer therapy consists mainly of small molecule inhibitors or monoclonal antibodies that inhibit the signal transduction pathways involved in growth, proliferation, and survival. Immune checkpoint inhibitors, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), antibody–drug conjugates (ADC), and antibody-directed enzyme prodrug therapy (ADEPT) are some of the recent molecular targeted cancer therapies.

This Special Issue aims to receive relevant contributions and recent insight into identifying druggable targets and discovering new drugs with different chemical entities or modes of action. We also seek contributions to finding or developing cancer small molecule inhibitors with higher specificity to cancer cells to increase efficacy and minimize toxicity. We are also keen to collect contributions to the patient microbiome's role in molecular targeted cancer therapy, such as cancer development, cancer progression and metastasis, and drug resistance and toxicity.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)